Transderm-V
Natural health product licensed in Canada
- Licence holder
- Sandoz Canada Inc.
- NPN or DIN-HM
- 80024336
- Status
- Inactive licence
- Licence date
- 22 March 2011
- Revision date
- 28 May 2019
- Form
- Timbre transdermique
- Route of administration
- Transdermique
- Application type
- Non traditionnelle
Oral dose analysis does not apply without an established exclusively oral route.
Composition
Medicinal composition not provided.
Non-medicinal ingredients
Light mineral oil, Polyisobutylene 1200000, Polyisobutylene 35000
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1 patch | Not specified |
Uses authorised in Canada
Text supplied in English because no French text is available.
Prevention of symptoms of motion sickness such as nausea and vomiting. To help in the prevention of nausea and vomiting in postoperative patients.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80024336
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2019. Photograph the packaging to check whether it has changed. Photograph the packaging